Pacira BioSciences Divests iovera° Business to Zimmer Biomet for Up to $140 Million

BioLife Solutions Acquires PanTHERA CryoSolutions

April 10, 2025

Biotechnology

BioLife Solutions acquired the remaining 90% of PanTHERA CryoSolutions for $9.3 million in cash plus 241,355 shares of BioLife common stock, with up to an additional $7.2 million of stock payable upon achievement of milestones. The acquisition adds PanTHERA's proprietary Ice Recrystallization Inhibitor (IRI) technology and scientific talent to BioLife's biopreservation consumables portfolio, accelerating product capability development for the cell and gene therapy market.

Zimmer Biomet to Acquire OrthoGrid Systems

August 7, 2024

Medical Devices

Zimmer Biomet Holdings, Inc. has signed a definitive agreement to acquire OrthoGrid Systems, Inc., a privately held medical technology company focused on AI-driven surgical guidance for total hip replacement. The deal adds OrthoGrid’s Hip AI fluoroscopy-based surgical assistance platform, two additional FDA-cleared orthopedic applications, and more than 40 patents, and is expected to close by the end of Q4 2024 subject to customary conditions.

Harmony Biosciences Acquires Zynerba Pharmaceuticals

August 14, 2023

Pharmaceuticals

Harmony Biosciences Holdings, Inc. has signed a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. in a cash tender offer valued at $60 million at closing ($1.1059 per share) plus a non-tradeable contingent value right (CVR) with potential additional payments of up to $140 million, for total potential consideration of up to $200 million. The deal is expected to close in the fourth quarter of 2023, subject to customary closing conditions and tendering by at least a majority of Zynerba’s outstanding shares.

Pacira BioSciences Acquires Flexion Therapeutics

October 11, 2021

Pharmaceuticals

Pacira BioSciences agreed to acquire Flexion Therapeutics for $8.50 per share in cash plus one contingent value right (CVR) worth up to $8.00 per share tied to sales and regulatory milestones. The deal adds Flexion's marketed non-opioid OA knee pain therapy ZILRETTA and its clinical-stage pipeline to Pacira's non-opioid pain management portfolio; the transaction was expected to close in Q4 2021 and to be accretive to Pacira's earnings.

Zimmer Biomet Acquires A&E Medical Corporation

December 1, 2020

Medical Devices

Zimmer Biomet completed the acquisition of A&E Medical Corporation from private equity owner Vance Street Capital for $250 million. A&E Medical, headquartered in Farmingdale, New Jersey, is a designer and manufacturer of sternal closure systems, cardiac pacing wires and related disposable surgical products; the deal expands Zimmer Biomet's capabilities and product portfolio in cardiovascular and cardiothoracic surgical devices.

Novartis Acquires Vedere Bio

September 30, 2020

Biotechnology

Novartis has acquired Vedere Bio, a Cambridge-based optogenetics AAV gene therapy company, for $150 million upfront plus up to $130 million in potential regulatory and clinical milestones (total consideration of $280 million). The deal includes Vedere Bio's lead preclinical intravitreal AAV programs focused on pan-genotypic vision restoration; earlier-stage assets were spun out into a newly formed independent company, Vedere Bio II.